The primary aim of this study is to test that apixaban is superior to aspirin for the prevention of recurrent stroke in subjects with cryptogenic ischemic stroke and atrial cardiopathy. Another ais is to test that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.
|Principal Investigator||Wady Aude, MD|
|Sponsor||National Institute of Neurological Disorders and Stroke|
|Type of Trial||Prospective|